Nivolumab Immunotherapy Preparation from Japan
Mixed nivolumab monoclonal antibody product for PD-1 inhibition in cancer immunotherapy. HTS 3002.14.0010 classification for bulk mixed immunological containing monoclonals for clinical trials. Includes sucrose stabilizer and buffer system.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• For clinical trial material, include IRB approval and protocol summaries
• Ensure GMP certification for manufacturing site; provide batch release docs
• Avoid retail packing to maintain bulk classification advantage